Brittany Lovely
Articles
Luspatercept Linked With Maintained Reduction in Transfusion Dependence Among Patients With β-Thalassemia
June 24, 2022
Article
Updated data from the phase 3 BELIEVE trial revealed a sustained reduction in the need for red blood cell transfusions among patients with β-thalassemia who received treatment with luspatercept-aamt.
Pediatric/Young Adult Patients With B-ALL Continue to Derive Benefit From Tisagenlecluecel at 5-Year Follow-Up
June 22, 2022
Article
Heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia maintained response with tisagenlecelucel according to long-term follow-up data from the phase 2 ELIANA trial.
All Patients With dMMR Rectal Cancer Experience Clinical Complete Response With Dostarlimab In Phase 2 Trial
June 08, 2022
Article
At data cutoff, all treated patients in a phase 2 trial experienced a clinical complete response with single-agent dostarlimab-gxly.
Sacituzumab Govitecan Outperforms Chemotherapy in HR+/HER2- Metastatic Breast Cancer
June 04, 2022
Article
Sacituzumab govitecan elicited a statistically significant and clinically meaningful benefit among patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
New Strategies Provide Faster Access To Cancer Care For Patients
May 27, 2022
Article
Pilot programs based out of Yale Cancer Center and Moffitt Cancer Center seek to improve access for newly diagnosed patients with cancer.
Regardless of HER2 Expression, Responses Are Showcased With Sacituzumab Govitecan in TNBC
May 26, 2022
Article
Sacituzumab govitecan-hziy significantly improved progression-free survival in patients with HER2-low expressing TNBC and HER2-negative disease.
Trastuzumab Deruxtecan Continues to Elicit Responses in HER2+ Breast Cancer With Active Brain Metastases
May 09, 2022
Article
Patients with HER2-positive breast cancer who also have brain metastases experienced clinical benefit with fam-trastuzumab deruxtecan-nxki in the phase 2 TUEXEDO-trial.
E-Selectin Represents Promising Direction for AML Treatment Focus
April 02, 2022
Article
Investigators are seeking to overcome barriers to help patients with acute myeloid leukemia achieve complete and durable remissions by focusing their attention on novel agents engineered to target adhesion factors.
Early Target Identification Will Help Maximize Osimertinib Treatment
August 28, 2021
Article
Identifying targets early can help forestall resistance and improve the efficacy of osimertinib, a EGFR tyrosine kinase inhibitor, in the first-line setting.
Triplet Chemotherapy Combination a Viable Option for Colorectal Cancer Mutation
August 03, 2021
Article
A combination of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) in the first-line setting was tested for efficacy in patients with BRAF V600E–mutant CRC.